Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Breast Neoplasms 3Uterine Cervical Neoplasms 1Stomach Neoplasms 1Risk Reduction Behavior 1Patient Preference 1Patient Acceptance of Health Care 1Health Behavior 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Disease 1Behavior 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Surgical Procedures, Operative 36Radiation 36Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × Risk Assessment × Clear all
NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting
21,000 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡